Samsara BioCapital, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001744967

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 · 27 positions · Total reported value $1.05B · Top-10 concentration 87.9% · Updated 2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

Turnover: 37.0% · 3 new · 7 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q3 2026 13F filing, Samsara BioCapital, LLC disclosed 27 equity positions with a combined reported value of $1.05B. The filing implies a focused portfolio: its ten largest positions account for 87.9% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were SRRK ($333.29M), MLYS ($147.54M), SEPN ($119.99M). By sector, the heaviest allocations are Health Care 91.8%, Industrials 8.0%. Versus the prior quarter, allocation shifted toward Industrials (+2.5pp) and away from Health Care (-2.6pp).

Versus the prior quarter, Samsara BioCapital, LLC opened 3 new positions, trimmed 7 and fully exited 0, a turnover rate of 37.0% of positions. The portfolio's overlap with the prior quarter was 89% of names.

The largest new positions opened in Q3 2026 were PMVP ($12.09M), VRDN ($11.49M), TLGYF ($1.25M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • PMVP PMV PHARMACEUTICALS INC · $12.09M
  • VRDN VIRIDIAN THERAPEUTICS INC · $11.49M
  • TLGYF TCGX ACQUISITION CORP · $1.25M

Fully Exited (vs previous quarter)

No tracked position was fully exited this quarter.

Insider Transactions (Form 4)

Latest Samsara BioCapital, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Samsara BioCapital, LLC files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 27 positions worth $1.05B in total. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • SEC registration: 801-113741 (status: Approved), registered 2018-07-27
  • Regulatory AUM (Form ADV): $2.17B as of 2026-10-28
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 3 private funds

Portfolio Structure

  • 27 positions · $1.05B reported value (Q3 2026)
  • Top 10 holdings = 87.9% of reported value
  • Largest position: SRRK (SCHOLAR ROCK HLDG CORP) at 31.7%
  • Average position size: $38.95M

Sector Tilt

  • Health Care 91.8%
  • Industrials 8.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 3 new, 3 added, 7 reduced
  • 14 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund increased exposure to core holdings (weights rose for 8/10 top positions), suggesting confidence in current biotech/healthcare bets, while selectively reducing one position (SEPN). 2. Key moves: - Added: ALMS (weight -9.59% points, shares +14.0% QoQ), NGNE (weight +0.50% points, shares +8.7% QoQ). - Reduced: SEPN (weight +2.75% points, shares -2.6% QoQ; note weight rose due to price, not sales). 3. Portfolio structure: Active, concentrated (27 positions), heavily biased toward Health Care (9/10 top holdings), with high risk appetite (small-cap biotech/therapeutics). 4. Per-holding one-liner: - SRRK: Scholar Rock (biopharma, unverified); MLYS: Mineralys Therapeutics (kidney disease, unverified); SEPN: Septerna (GI disorders, unverified); ALMR: Alamar Biosciences (cancer diagnostics, unverified); SGP: Spyglass Pharma (rare diseases, unverified); ALMS: Alumis (immunology, unverified); NGNE: Neurogene (gene therapy, unverified); KLRS: Kalaris Therapeutics (metabolic diseases, unverified); IVA: Inventiva (lysosomal storage disorders, unverified); PBLS: Parabilis (fibrosis, unverified). 5. Style summary: Biotech-focused fund with conviction in long-term holdings, selectively trimming underperformers while adding to high-conviction names.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 10:58

Sector Allocation

Health Care 91.8%
Other 0.1%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 6.90M $333.29M 31.69%
31.69%
Hold
2 5.87M $147.54M 14.03%
14.03%
Hold
3 3.07M $119.99M 11.41%
11.41%
Reduce
4 2.48M $84.50M 8.04%
8.04%
Hold
5 2.11M $54.86M 5.22%
5.22%
Hold
6 7.24M $53.47M 5.08%
5.08%
Add
7 1.87M $51.94M 4.94%
4.94%
Add
8 12.88M $37.23M 3.54%
3.54%
Hold
9 6.31M $23.30M 2.22%
2.22%
Hold
10 556.04K $17.95M 1.71%
1.71%
Hold
11 1.06M $17.12M 1.63%
1.63%
Hold
12 7.24M $12.09M 1.15%
1.15%
New
13 837.17K $11.49M 1.09%
1.09%
New
14 2.43M $11.27M 1.07%
1.07%
Reduce
15 354.73K $10.94M 1.04%
1.04%
Add
16 736.24K $10.34M 0.98%
0.98%
Hold
17 3.51M $9.19M 0.87%
0.87%
Hold
18 10.37M $8.20M 0.78%
0.78%
Hold
19 954.86K $6.80M 0.65%
0.65%
Hold
20 594.75K $6.60M 0.63%
0.63%
Reduce
21 400.00K $6.12M 0.58%
0.58%
Hold
22 55.09K $5.46M 0.52%
0.52%
Hold
23 3.38M $4.09M 0.39%
0.39%
Reduce
24 1.35M $3.91M 0.37%
0.37%
Reduce
25 300.36K $1.58M 0.15%
0.15%
Reduce
26 100.00K $1.25M 0.12%
0.12%
New
27 87.96K $1.04M 0.10%
0.10%
Reduce

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 90% R 90% F1 90% (modelled on 2026-Q2; 9/10 hit)

Historical Backtest (11 quarters)

Avg precision 84% · recall 84% · F1 84% · avg rank error 1.8 · Top-10 turnover 19%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 70% 70% 70% SRRK · RYZB · CRGX · MLYS · NGNE · ACLX · GRPH · SLRN · NKTX · SYRS SRRK · CRGX · MLYS · NGNE · NKTX · ACLX · LENZ · LYRA · SLRN · AVDL
2024-Q2 80% 80% 80% SRRK · CRGX · MLYS · NGNE · NKTX · ACLX · LENZ · LYRA · SLRN · AVDL CRGX · MLYS · SRRK · NGNE · ACLX · CLYM · NKTX · LENZ · AVDL · JSPR
2024-Q3 90% 90% 90% CRGX · MLYS · SRRK · NGNE · ACLX · CLYM · NKTX · LENZ · AVDL · JSPR CRGX · MLYS · SRRK · NGNE · ALMS · ACLX · LENZ · NKTX · CLYM · AVDL
2024-Q4 70% 70% 70% CRGX · MLYS · SRRK · NGNE · ALMS · ACLX · LENZ · NKTX · AVDL · CLYM SRRK · CRGX · SEPN · MLYS · NGNE · UPB · LENZ · ALMS · ACLX · ZYME
2025-Q1 80% 80% 80% SRRK · CRGX · SEPN · MLYS · NGNE · UPB · LENZ · ALMS · ACLX · ZYME SRRK · KLRS · MLYS · NGNE · ALMS · PVLA · SEPN · CRGX · LENZ · UPB
2025-Q2 100% 100% 100% SRRK · KLRS · MLYS · NGNE · ALMS · PVLA · SEPN · CRGX · LENZ · UPB SRRK · MLYS · SEPN · KLRS · NGNE · CRGX · UPB · ALMS · LENZ · PVLA
2025-Q3 90% 90% 90% SRRK · MLYS · SEPN · KLRS · NGNE · CRGX · ALMS · UPB · LENZ · GOSS MLYS · SRRK · KLRS · SEPN · NGNE · ALMS · UPB · GOSS · LENZ · AQST
2025-Q4 90% 90% 90% MLYS · SRRK · KLRS · SEPN · NGNE · ALMS · UPB · GOSS · LENZ · AQST SRRK · MLYS · KLRS · SEPN · ALMS · NGNE · IVA · GOSS · UPB · AQST
2026-Q1 80% 80% 80% SRRK · MLYS · KLRS · SEPN · ALMS · NGNE · IVA · GOSS · UPB · JBIO SRRK · MLYS · ALMS · SEPN · KLRS · SGP · NGNE · IVA · STRO · JBIO
2026-Q2 90% 90% 90% SRRK · MLYS · ALMS · KLRS · SEPN · SGP · NGNE · STRO · IVA · JBIO SRRK · ALMS · MLYS · SEPN · ALMR · NGNE · KLRS · SGP · STRO · IVA
2026-Q3 ★ 90% 90% 90% SRRK · ALMS · MLYS · SEPN · ALMR · NGNE · KLRS · SGP · STRO · IVA SRRK · MLYS · SEPN · ALMR · SGP · ALMS · NGNE · KLRS · IVA · PBLS

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

Barra Factor Attribution

The disclosed long US equity book from the 2026-Q3 13F is held at its report-date weights and decomposed over 2026-09-30 ~ 2026-11-16. The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional factor returns and an EWMA factor covariance for risk. The “portfolio” is the visible 13F book, not the fund's true NAV.

13F periodQ3 2026 Attribution quarterQ4 2026 (in progress) Window2026-09-30 → 2026-11-16 Trading days33 Holdings4 Model coverage100.0%

The quarter is not complete yet; the window ends at the latest available price date, 2026-11-16, and will update as prices arrive.

Portfolio return-8.61%Buy & hold
QQQ synthetic benchmark-17.01%Liquidity weighted
Excess return+8.40%vs benchmark
Barra annualised vol57.3%Model estimate
Realised vol54.5%Annualised in window
Weighted beta1.04Raw exposure
Factor / specific risk39% / 61%Share of variance
Top-10 concentration100.0%Of reported value
Portfolio value (start = 100)78.485.191.898.5105.310-0110-2311-16Samsara BioCapital, LLCQQQ syntheticLiquid universe EW
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.

1. Performance

Metric Value Note
Portfolio return (buy & hold)-8.61%Disclosed long book
QQQ synthetic benchmark-17.01%Liquidity-weighted constituents
Model universe, equal weight-1.70%Opportunity-cost reference
Excess return+8.40%Portfolio − benchmark
Arithmetic return sum-7.12%Difference vs compounded is the cross term
Weighted raw beta1.04Weighted holding betas
Realised volatility (annualised)54.45%Daily returns in window
Barra model volatility (annualised)57.34%Factor + specific
Factor share of variance39.3%Barra factors
Specific share of variance60.7%Stock residuals
Reported value$476.3M13F long US equity

2. Return attribution

The -7.12% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.

Factor group Factors Contribution Share of |return|
Size & Liquidity 6 +1.17% 16.4%
Momentum & Growth 3 -2.89% -40.6%
Volatility & Tail Risk 7 -6.10% -85.7%
Industry 12 +5.79% 81.2%
Specific 1 -5.08% -71.4%
Return attribution (style + industry, %)-13.9-6.9+0.0+6.9+13.9Short-term Reversal+0.68Turnover+0.74Beta+0.80Leverage (Downside Vol)+0.85Amihud Illiquidity-1.23Growth-1.37Momentum-2.20Skewness-3.06Non-linear Size+3.10Size+3.23Mid Cap-5.17Health Care+5.75Residual Volatility+8.65Historical Volatility-12.83
Factor Type Exposure Factor return Contribution Share of |return|
Residual Volatility Style +2.63 +3.29% +8.65% 121.4%
Health Care Industry +0.82 +6.98% +5.75% 80.7%
Size Style -1.66 -1.95% +3.23% 45.4%
Non-linear Size Style +3.07 +1.01% +3.10% 43.5%
Leverage (Downside Vol) Style -0.49 -1.71% +0.85% 11.9%
Beta Style +0.18 +4.44% +0.80% 11.2%
Turnover Style -0.15 -4.80% +0.74% 10.4%
Short-term Reversal Style +0.78 +0.87% +0.68% 9.6%
Liquidity Style +1.37 +0.36% +0.49% 6.8%
Kurtosis Style -0.03 +7.51% -0.23% -3.3%
Max Drawdown Style +0.15 -1.76% -0.26% -3.7%
Amihud Illiquidity Style +2.75 -0.45% -1.23% -17.2%
Growth Style -0.79 +1.75% -1.37% -19.3%
Momentum Style +0.55 -4.00% -2.20% -30.9%
Skewness Style +0.70 -4.39% -3.06% -43.0%
Specific Specific — — -5.08% -71.4%
Mid Cap Style +2.67 -1.94% -5.17% -72.6%
Historical Volatility Style +0.92 -14.00% -12.83% -180.2%

3. Risk attribution

Annualised volatility is 57.34%; factor risk explains 39.3% of variance and specific risk 60.7%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.

Risk attribution (share of variance, %)-65.6-32.8+0.0+32.8+65.6Growth-0.37Skewness-0.24Max Drawdown+0.26Beta+0.90Amihud Illiquidity+1.12Industrials+1.69Size+2.00Liquidity+3.20Non-linear Size+3.74Historical Volatility+4.80Health Care+5.42Mid Cap+7.21Residual Volatility+9.63Specific+60.72
Factor Type Exposure Share of variance Vol contribution Share of vol
Specific Specific — 60.7% +34.82% 34.8%
Residual Volatility Style +2.63 9.6% +5.52% 5.5%
Mid Cap Style +2.67 7.2% +4.13% 4.1%
Health Care Industry +0.82 5.4% +3.11% 3.1%
Historical Volatility Style +0.92 4.8% +2.75% 2.8%
Non-linear Size Style +3.07 3.7% +2.14% 2.1%
Liquidity Style +1.37 3.2% +1.83% 1.8%
Size Style -1.66 2.0% +1.15% 1.1%
Industrials Industry +0.18 1.7% +0.97% 1.0%
Amihud Illiquidity Style +2.75 1.1% +0.64% 0.6%
Beta Style +0.18 0.9% +0.52% 0.5%
Max Drawdown Style +0.15 0.3% +0.15% 0.1%
Skewness Style +0.70 -0.2% -0.14% -0.1%
Growth Style -0.79 -0.4% -0.21% -0.2%

4. Style exposures

Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.

Style exposures (z-score)-2.1-0.70.72.13.5Max DrawdownKurtosisSkewnessLeverage (Downside Vol)GrowthTurnoverAmihud IlliquidityLiquidityHistorical VolatilityResidual VolatilityShort-term ReversalMomentumBetaMid CapNon-linear SizeSizePortfolioQQQ benchmark
Style factor Portfolio QQQ benchmark Difference
Size -1.66 +2.10 -3.76
Non-linear Size +3.07 +1.68 +1.39
Mid Cap +2.67 +0.13 +2.54
Beta +0.18 +1.29 -1.11
Momentum +0.55 +0.72 -0.17
Short-term Reversal +0.78 -0.64 +1.42
Residual Volatility +2.63 -0.40 +3.03
Historical Volatility +0.92 +0.86 +0.06
Liquidity +1.37 +0.11 +1.25
Amihud Illiquidity +2.75 +1.16 +1.60
Turnover -0.15 +0.21 -0.36
Growth -0.79 +0.58 -1.37
Leverage (Downside Vol) -0.49 +0.14 -0.64
Skewness +0.70 +0.24 +0.46
Kurtosis -0.03 +0.21 -0.25
Max Drawdown +0.15 -0.08 +0.23

5. Industry allocation & Brinson

Industry allocation (weight, %)-8.216.541.165.890.5Information TechnologyCommunication ServicesUtilitiesConsumer StaplesConsumer DiscretionaryIndustrialsHealth CarePortfolioQQQ benchmark
Sector Portfolio Benchmark Portfolio ret Benchmark ret Allocation Selection Interaction Total
Information Technology 0.0% 73.6% +0.00% -22.33% +3.83% +16.44% -16.44% +16.44%
Communication Services 0.0% 2.6% +0.00% -17.64% +0.01% +0.46% -0.46% +0.46%
Utilities 0.0% 0.8% +0.00% +11.13% -0.22% -0.09% +0.09% -0.09%
Consumer Staples 0.0% 0.8% +0.00% +15.26% -0.27% -0.13% +0.13% -0.13%
Consumer Discretionary 0.0% 8.8% +0.00% +3.76% -1.84% -0.33% +0.33% -0.33%
Industrials 17.7% 11.1% -10.33% +4.36% +1.43% -1.63% -0.97% -2.32%
Health Care 82.3% 1.7% -9.59% +8.29% +20.47% -0.31% -14.39% -8.03%
Total +23.29% +14.38% -31.69% +5.98%

6. Holdings & contribution

Symbol Name Sector Weight Return Contribution QoQ
SRRK SCHOLAR ROCK HLDG CORP Health Care 69.97% -7.82% -5.47% Hold
ALMR ALAMAR BIOSCIENCES INC Industrials 17.74% -10.33% -1.83% Hold
NGNE NEUROGENE INC Health Care 10.90% -16.25% -1.77% Add
AGMB AGOMAB THERAPEUTICS NV Health Care 1.39% -46.22% -0.64% Reduce
Contribution rank Symbol Sector Weight Return Contribution
1 AGMB Health Care 1.39% -46.22% -0.64%
2 NGNE Health Care 10.90% -16.25% -1.77%
3 ALMR Industrials 17.74% -10.33% -1.83%
4 SRRK Health Care 69.97% -7.82% -5.47%

7. Conclusions

  1. Over the attribution window 2026-09-30 → 2026-11-16 (33 trading days), the reported portfolio returned -8.61%, versus -17.01% for the QQQ synthetic benchmark — an excess of +8.40%.
  2. Return attribution: the largest positive style/industry contributions came from Residual Volatility +8.65%, Health Care +5.75%, Size +3.23%; the largest drags came from Historical Volatility -12.83%, Mid Cap -5.17%, Skewness -3.06%. Specific (stock-level) return contributed -5.08%.
  3. Risk attribution: Barra model volatility is 57.34% annualised; factor risk explains 39% of variance and specific risk 61%. The largest factor risk sources are Residual Volatility 9.6%, Mid Cap 7.2%, Health Care 5.4%.
  4. Style tilt: size -1.66, momentum +0.55, volatility +0.92, liquidity +1.37; the weighted raw beta is 1.04. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
  5. Industry: the largest overweight versus the benchmark is Health Care (+80.5 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +23.29%, selection +14.38% and interaction -31.69%.
  6. Concentration: the top-10 positions are 100.0% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
  • 13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
  • Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
  • Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
  • The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
  • Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
  • 13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
  • Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.

FAQ

What did Samsara BioCapital, LLC buy in 2026-Q3?

In its 2026-Q3 13F filing, Samsara BioCapital, LLC reported 27 equity positions worth $1.05B in aggregate; its largest disclosed positions were SRRK ($333.29M), MLYS ($147.54M), SEPN ($119.99M).

How large is Samsara BioCapital, LLC's portfolio?

Samsara BioCapital, LLC reported $1.05B of long equity holdings across 27 positions as of 2026-Q3. Top-10 holdings account for 87.9% of reported value.

What is Samsara BioCapital, LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/samsara-biocapital/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →